Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Jul 21, 2024; 30(27): 3304-3313
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3304
Table 1 Baseline characteristics of patients, n (%)

Total
BQT
VAT-10
VAT-14
P value
Age (years, mean ± SD)45.15 ± 12.5343.84 ± 14.2645.52 ± 11.2645.69 ± 12.390.428
Range12.00-80.0015.00-72.0027.00-80.0012.00-77.00
Gender0.027
Male164 (53.59)48 (51.06)64 (64.00)45 (45.45)
Female 142 (46.41)46 (48.94)36 (36.00)54 (54.55)
Diagnosis0.754
Peptic ulcer42 (13.73)15 (14.85)12 (11.65)15 (14.71)
Non-ulcer dyspepsia264 (86.72)86 (85.15)91 (88.35)87 (85.29)
Cigarette smoking33 (10.78)12 (12.77)9 (9.00)9 (9.09)0.618
Alcohol drinking14 (4.58)6 (6.38)4 (4.00)3 (3.03)0.524
Tea drinking41 (13.40)15 (15.96)14 (14.00)10 (10.10)0.473
Coffee drinking18 (5.88)6 (6.38)2 (2.00)9 (9.09)0.097
Family history of gastric cancer17 (5.56)4 (4.26)4 (4.00)5 (5.05)0.940
H. pylori family gathering51 (16.67)15 (15.96)15 (15.00)19 (19.19)0.581

  • Citation: Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol 2024; 30(27): 3304-3313
  • URL: https://www.wjgnet.com/1007-9327/full/v30/i27/3304.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v30.i27.3304